カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界の組換えヒトパピローマウイルス9価ワクチン市場予測2023-2029：女性、男性

【英語タイトル】Recombinant Human Papillomavirus 9-Valent Vaccine Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8631）・商品コード：MMG23LY8631
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：74
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の組換えヒトパピローマウイルス9価ワクチン市場規模と予測を収録しています。・世界の組換えヒトパピローマウイルス9価ワクチン市場：売上、2018年-2023年、2024年-2029年
・世界の組換えヒトパピローマウイルス9価ワクチン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の組換えヒトパピローマウイルス9価ワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「女性」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

組換えヒトパピローマウイルス9価ワクチンのグローバル主要企業は、GSK、 Merck(MSD)、 Beijing Wantaiなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、組換えヒトパピローマウイルス9価ワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の組換えヒトパピローマウイルス9価ワクチン市場：タイプ別、2018年-2023年、2024年-2029年
世界の組換えヒトパピローマウイルス9価ワクチン市場：タイプ別市場シェア、2022年
・女性、男性

世界の組換えヒトパピローマウイルス9価ワクチン市場：用途別、2018年-2023年、2024年-2029年
世界の組換えヒトパピローマウイルス9価ワクチン市場：用途別市場シェア、2022年
・病院、専門クリニック

世界の組換えヒトパピローマウイルス9価ワクチン市場：地域・国別、2018年-2023年、2024年-2029年
世界の組換えヒトパピローマウイルス9価ワクチン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における組換えヒトパピローマウイルス9価ワクチンのグローバル売上、2018年-2023年
・主要企業における組換えヒトパピローマウイルス9価ワクチンのグローバル売上シェア、2022年
・主要企業における組換えヒトパピローマウイルス9価ワクチンのグローバル販売量、2018年-2023年
・主要企業における組換えヒトパピローマウイルス9価ワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GSK、 Merck(MSD)、 Beijing Wantai

*************************************************************

・調査・分析レポートの概要
組換えヒトパピローマウイルス9価ワクチン市場の定義
市場セグメント
世界の組換えヒトパピローマウイルス9価ワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の組換えヒトパピローマウイルス9価ワクチン市場規模
世界の組換えヒトパピローマウイルス9価ワクチン市場規模：2022年 VS 2029年
世界の組換えヒトパピローマウイルス9価ワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの組換えヒトパピローマウイルス9価ワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の組換えヒトパピローマウイルス9価ワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：女性、男性
組換えヒトパピローマウイルス9価ワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、専門クリニック
組換えヒトパピローマウイルス9価ワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別組換えヒトパピローマウイルス9価ワクチン市場規模 2022年と2029年
地域別組換えヒトパピローマウイルス9価ワクチン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、 Merck(MSD)、 Beijing Wantai
...

This report aims to provide a comprehensive presentation of the global market for Recombinant Human Papillomavirus 9-Valent Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Papillomavirus 9-Valent Vaccine. This report contains market size and forecasts of Recombinant Human Papillomavirus 9-Valent Vaccine in global, including the following market information:
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Sales, 2018-2023, 2024-2029, (K Doses)
Global top five Recombinant Human Papillomavirus 9-Valent Vaccine companies in 2022 (%)
The global Recombinant Human Papillomavirus 9-Valent Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Women Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Papillomavirus 9-Valent Vaccine include GSK, Merck(MSD) and Beijing Wantai, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recombinant Human Papillomavirus 9-Valent Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Doses)
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Segment Percentages, by Type, 2022 (%)
Women
Men
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Doses)
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialty Clinic
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Doses)
Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Papillomavirus 9-Valent Vaccine revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Human Papillomavirus 9-Valent Vaccine revenues share in global market, 2022 (%)
Key companies Recombinant Human Papillomavirus 9-Valent Vaccine sales in global market, 2018-2023 (Estimated), (K Doses)
Key companies Recombinant Human Papillomavirus 9-Valent Vaccine sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Merck(MSD)
Beijing Wantai
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Human Papillomavirus 9-Valent Vaccine, market overview.
Chapter 2: Global Recombinant Human Papillomavirus 9-Valent Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Human Papillomavirus 9-Valent Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Human Papillomavirus 9-Valent Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Human Papillomavirus 9-Valent Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Recombinant Human Papillomavirus 9-Valent Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Human Papillomavirus 9-Valent Vaccine Overall Market Size
2.1 Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Size: 2022 VS 2029
2.2 Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Recombinant Human Papillomavirus 9-Valent Vaccine Players in Global Market
3.2 Top Global Recombinant Human Papillomavirus 9-Valent Vaccine Companies Ranked by Revenue
3.3 Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue by Companies
3.4 Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales by Companies
3.5 Global Recombinant Human Papillomavirus 9-Valent Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Recombinant Human Papillomavirus 9-Valent Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Recombinant Human Papillomavirus 9-Valent Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Human Papillomavirus 9-Valent Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Human Papillomavirus 9-Valent Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Human Papillomavirus 9-Valent Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Size Markets, 2022 & 2029
4.1.2 Women
4.1.3 Men
4.2 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue & Forecasts
4.2.1 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales & Forecasts
4.3.1 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2023
4.3.2 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2024-2029
4.3.3 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialty Clinic
5.2 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue & Forecasts
5.2.1 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales & Forecasts
5.3.1 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2023
5.3.2 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2024-2029
5.3.3 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue & Forecasts
6.2.1 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales & Forecasts
6.3.1 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2023
6.3.2 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2024-2029
6.3.3 By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2029
6.4.3 US Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.4.4 Canada Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.4.5 Mexico Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2029
6.5.3 Germany Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5.4 France Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5.5 U.K. Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5.6 Italy Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5.7 Russia Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.5.9 Benelux Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2029
6.6.3 China Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.6.4 Japan Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.6.5 South Korea Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.6.7 India Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2029
6.7.3 Brazil Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.7.4 Argentina Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Sales, 2018-2029
6.8.3 Turkey Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.8.4 Israel Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
6.8.6 UAE Recombinant Human Papillomavirus 9-Valent Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Recombinant Human Papillomavirus 9-Valent Vaccine Major Product Offerings
7.1.4 GSK Recombinant Human Papillomavirus 9-Valent Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Merck(MSD)
7.2.1 Merck(MSD) Company Summary
7.2.2 Merck(MSD) Business Overview
7.2.3 Merck(MSD) Recombinant Human Papillomavirus 9-Valent Vaccine Major Product Offerings
7.2.4 Merck(MSD) Recombinant Human Papillomavirus 9-Valent Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 Merck(MSD) Key News & Latest Developments
7.3 Beijing Wantai
7.3.1 Beijing Wantai Company Summary
7.3.2 Beijing Wantai Business Overview
7.3.3 Beijing Wantai Recombinant Human Papillomavirus 9-Valent Vaccine Major Product Offerings
7.3.4 Beijing Wantai Recombinant Human Papillomavirus 9-Valent Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Beijing Wantai Key News & Latest Developments
8 Global Recombinant Human Papillomavirus 9-Valent Vaccine Production Capacity, Analysis
8.1 Global Recombinant Human Papillomavirus 9-Valent Vaccine Production Capacity, 2018-2029
8.2 Recombinant Human Papillomavirus 9-Valent Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Human Papillomavirus 9-Valent Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Human Papillomavirus 9-Valent Vaccine Supply Chain Analysis
10.1 Recombinant Human Papillomavirus 9-Valent Vaccine Industry Value Chain
10.2 Recombinant Human Papillomavirus 9-Valent Vaccine Upstream Market
10.3 Recombinant Human Papillomavirus 9-Valent Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Human Papillomavirus 9-Valent Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Recombinant Human Papillomavirus 9-Valent Vaccine in Global Market
Table 2. Top Recombinant Human Papillomavirus 9-Valent Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Share by Companies, 2018-2023
Table 5. Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales by Companies, (K Doses), 2018-2023
Table 6. Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Recombinant Human Papillomavirus 9-Valent Vaccine Price (2018-2023) & (US$/Dose)
Table 8. Global Manufacturers Recombinant Human Papillomavirus 9-Valent Vaccine Product Type
Table 9. List of Global Tier 1 Recombinant Human Papillomavirus 9-Valent Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Recombinant Human Papillomavirus 9-Valent Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), 2018-2023
Table 15. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), 2024-2029
Table 16. By Application – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), 2018-2023
Table 20. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), 2024-2029
Table 21. By Region – Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), 2018-2023
Table 25. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), 2024-2029
Table 26. By Country - North America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2018-2023
Table 29. By Country - North America Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2024-2029
Table 30. By Country - Europe Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2018-2023
Table 33. By Country - Europe Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2024-2029
Table 34. By Region - Asia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2018-2023
Table 37. By Region - Asia Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2024-2029
Table 38. By Country - South America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2018-2023
Table 41. By Country - South America Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2024-2029
Table 42. By Country - Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2018-2023
Table 45. By Country - Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Sales, (K Doses), 2024-2029
Table 46. GSK Company Summary
Table 47. GSK Recombinant Human Papillomavirus 9-Valent Vaccine Product Offerings
Table 48. GSK Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 49. GSK Key News & Latest Developments
Table 50. Merck(MSD) Company Summary
Table 51. Merck(MSD) Recombinant Human Papillomavirus 9-Valent Vaccine Product Offerings
Table 52. Merck(MSD) Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 53. Merck(MSD) Key News & Latest Developments
Table 54. Beijing Wantai Company Summary
Table 55. Beijing Wantai Recombinant Human Papillomavirus 9-Valent Vaccine Product Offerings
Table 56. Beijing Wantai Recombinant Human Papillomavirus 9-Valent Vaccine Sales (K Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 57. Beijing Wantai Key News & Latest Developments
Table 58. Recombinant Human Papillomavirus 9-Valent Vaccine Production Capacity (K Doses) of Key Manufacturers in Global Market, 2021-2023 (K Doses)
Table 59. Global Recombinant Human Papillomavirus 9-Valent Vaccine Capacity Market Share of Key Manufacturers, 2021-2023
Table 60. Global Recombinant Human Papillomavirus 9-Valent Vaccine Production by Region, 2018-2023 (K Doses)
Table 61. Global Recombinant Human Papillomavirus 9-Valent Vaccine Production by Region, 2024-2029 (K Doses)
Table 62. Recombinant Human Papillomavirus 9-Valent Vaccine Market Opportunities & Trends in Global Market
Table 63. Recombinant Human Papillomavirus 9-Valent Vaccine Market Drivers in Global Market
Table 64. Recombinant Human Papillomavirus 9-Valent Vaccine Market Restraints in Global Market
Table 65. Recombinant Human Papillomavirus 9-Valent Vaccine Raw Materials
Table 66. Recombinant Human Papillomavirus 9-Valent Vaccine Raw Materials Suppliers in Global Market
Table 67. Typical Recombinant Human Papillomavirus 9-Valent Vaccine Downstream
Table 68. Recombinant Human Papillomavirus 9-Valent Vaccine Downstream Clients in Global Market
Table 69. Recombinant Human Papillomavirus 9-Valent Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Recombinant Human Papillomavirus 9-Valent Vaccine Segment by Type in 2022
Figure 2. Recombinant Human Papillomavirus 9-Valent Vaccine Segment by Application in 2022
Figure 3. Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Recombinant Human Papillomavirus 9-Valent Vaccine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, 2018-2029 (US$, Mn)
Figure 7. Recombinant Human Papillomavirus 9-Valent Vaccine Sales in Global Market: 2018-2029 (K Doses)
Figure 8. The Top 3 and 5 Players Market Share by Recombinant Human Papillomavirus 9-Valent Vaccine Revenue in 2022
Figure 9. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 11. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 12. By Type - Global Recombinant Human Papillomavirus 9-Valent Vaccine Price (US$/Dose), 2018-2029
Figure 13. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 15. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 16. By Application - Global Recombinant Human Papillomavirus 9-Valent Vaccine Price (US$/Dose), 2018-2029
Figure 17. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 20. By Region - Global Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 21. By Country - North America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 22. By Country - North America Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 23. US Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 28. Germany Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 29. France Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 37. China Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 41. India Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 43. By Country - South America Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 44. Brazil Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Recombinant Human Papillomavirus 9-Valent Vaccine Sales Market Share, 2018-2029
Figure 48. Turkey Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Recombinant Human Papillomavirus 9-Valent Vaccine Revenue, (US$, Mn), 2018-2029
Figure 52. Global Recombinant Human Papillomavirus 9-Valent Vaccine Production Capacity (K Doses), 2018-2029
Figure 53. The Percentage of Production Recombinant Human Papillomavirus 9-Valent Vaccine by Region, 2022 VS 2029
Figure 54. Recombinant Human Papillomavirus 9-Valent Vaccine Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界の組換えヒトパピローマウイルス9価ワクチン市場予測2023-2029：女性、男性] (コード：MMG23LY8631)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の組換えヒトパピローマウイルス9価ワクチン市場予測2023-2029：女性、男性]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の二価ヒトパピローマウイルスワクチン市場2022年：HPV16、HPV18
  • 世界の組換え第VIII因子市場予測2023-2029：200IU、250IU
  • 世界の組換え凝固第IX因子市場予測2023-2029：500IU、1000IU、その他
  • 世界の不活化ポリオウイルスワクチン市場予測2023-2029：ヒト二倍体細胞、サル腎臓細胞
  • 世界の吸入式鼻腔インフルエンザワクチン市場予測2023-2029：弱毒生インフルエンザワクチン、分割インフルエンザワクチン

    • ◆H&Iグローバルリサーチのお客様（例）◆